Prelude Historical Income Statement
| PRLD Stock | USD 0.98 0.02 2.08% |
Historical analysis of Prelude Therapeutics income statement accounts such as Other Operating Expenses of 86.4 M, Research Development of 67.5 M, Total Operating Expenses of 86.4 M or Reconciled Depreciation of 827.2 K can show how well Prelude Therapeutics performed in making a profits. Evaluating Prelude Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Prelude Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Prelude Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Prelude Therapeutics is a good buy for the upcoming year.
Prelude |
About Prelude Income Statement Analysis
Prelude Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Prelude Therapeutics shareholders. The income statement also shows Prelude investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Prelude Therapeutics Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Prelude Therapeutics. It is also known as Prelude Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Prelude Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Prelude Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Prelude Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Prelude Stock refer to our How to Trade Prelude Stock guide.At present, Prelude Therapeutics' Total Other Income Expense Net is projected to increase significantly based on the last few years of reporting. The current year's Cost Of Revenue is expected to grow to about 1.6 M, whereas Selling General Administrative is forecasted to decline to about 18.9 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Reconciled Depreciation | 915K | 1.3M | 1.2M | 827.2K | Total Operating Expenses | 113.7M | 123.5M | 132.3M | 86.4M |
Prelude Therapeutics income statement Correlations
Click cells to compare fundamentals
Prelude Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Prelude Therapeutics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 382K | 542K | 915K | 1.3M | 1.2M | 821.5K | |
| Selling General Administrative | 3.8M | 10.6M | 27.0M | 30.7M | 28.9M | 18.9M | |
| Other Operating Expenses | 28.1M | 58.8M | 113.7M | 123.5M | 132.3M | 86.4M | |
| Operating Income | (28.1M) | (58.8M) | (113.7M) | (123.5M) | (132.3M) | (125.7M) | |
| Net Income From Continuing Ops | (27.6M) | (56.9M) | (111.7M) | (115.4M) | (117.4M) | (123.3M) | |
| Ebit | (28.1M) | (58.8M) | (113.7M) | (123.5M) | (132.3M) | (125.7M) | |
| Research Development | 24.3M | 48.2M | 86.8M | 92.9M | 103.4M | 67.5M | |
| Ebitda | (27.7M) | (58.2M) | (112.8M) | (122.2M) | (131.1M) | (124.6M) | |
| Total Operating Expenses | 28.1M | 58.8M | 113.7M | 123.5M | 132.3M | 86.4M | |
| Reconciled Depreciation | 382K | 542K | 915K | 1.3M | 1.2M | 827.2K | |
| Income Before Tax | (27.6M) | (56.9M) | (111.7M) | (115.4M) | (121.8M) | (115.7M) | |
| Total Other Income Expense Net | 539K | 1.8M | 2.0M | 8.1M | 10.4M | 11.0M | |
| Net Income Applicable To Common Shares | (27.6M) | (56.9M) | (111.7M) | (115.4M) | (103.9M) | (109.1M) | |
| Net Income | (27.6M) | (56.9M) | (110.8M) | (107.3M) | (121.8M) | (115.7M) | |
| Income Tax Expense | (539K) | 335.7K | (915K) | (8.1M) | (1.0) | (1.05) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Prelude Therapeutics is a strong investment it is important to analyze Prelude Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Prelude Therapeutics' future performance. For an informed investment choice regarding Prelude Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Prelude Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Prelude Stock refer to our How to Trade Prelude Stock guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Prelude Therapeutics. If investors know Prelude will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Prelude Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.77) | Revenue Per Share 0.04 | Return On Assets (0.39) | Return On Equity (0.67) |
The market value of Prelude Therapeutics is measured differently than its book value, which is the value of Prelude that is recorded on the company's balance sheet. Investors also form their own opinion of Prelude Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Prelude Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Prelude Therapeutics' market value can be influenced by many factors that don't directly affect Prelude Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Prelude Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Prelude Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Prelude Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.